Processa Pharmaceuticals, Inc.PCSAEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for patients with high unmet medical needs. Its core product pipeline targets rare diseases, gastrointestinal disorders, and dermatological conditions, with primary operational focus on the North American and European healthcare markets.
Insider Transactions
Net 90d: +$103.1K · buys $103.1K / sells $0Range:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-30 | Wendy Guy | Chief Administrative Officer | Buy (open market) | 1.7K | $2.69 | $4.7K |
| 2026-04-30 | Sian Bigora | Chief Development Officer | Buy (open market) | 2.0K | $2.69 | $5.3K |
| 2026-04-30 | Patrick Lin | Chief Business - Strategy Off | Buy (open market) | 1.5K | $2.69 | $4.1K |
| 2026-04-30 | Ng George K | Chief Executive Officer | Buy (open market) | 2.0K | $2.69 | $5.5K |
| 2026-04-30 | David Young | Pres. Research & Development | Buy (open market) | 1.7K | $2.69 | $4.6K |
| 2026-04-30 | SKIBSTED RUSSELL | Chief Financial Officer | Buy (open market) | 2.2K | $2.69 | $5.9K |
| 2026-04-15 | David Young | Pres. Research & Development | Buy (open market) | 1.5K | $2.97 | $4.6K |
| 2026-04-15 | Sian Bigora | Chief Development Officer | Buy (open market) | 1.8K | $2.97 | $5.3K |
| 2026-04-15 | SKIBSTED RUSSELL | Chief Financial Officer | Buy (open market) | 2.0K | $2.97 | $5.9K |
| 2026-04-15 | Ng George K | Chief Executive Officer | Buy (open market) | 1.8K | $2.97 | $5.5K |
1–10 of 21
Page 1 / 3